| Característica |
Objectiu de la convocatòria
The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias.
|
Característiques principals
FUNDING MECHANISMS:
Drug Development RFP: The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias.
The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.
Neuroimaging and CSF Biomarker Development RFP: The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
Prevention Pipeline RFP: The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
|
Lloc de presentació
IMIM and PSMAR staff who need more information should contact::
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: cbarnwell@imim.es Ext.: 1670
Marta López: mlopez4@imim.es Ext.: 1576
|
Convocatòria (URL)
https://www.alzdiscovery.org/research-and-grants/funding-opportunities
|
Requisits
Funding is open to researchers and clinicians worldwide at
Academic medical centers and universities or nonprofits. Industry partnerships are encouraged
Biotechnology companies. Existing companies and new startups are both eligible.
|
Dotació
Drug development: Up to $5,000,000 based on stage and scope of research.
Neuroimaging and CSF biomarker development program: up to $600,000
Prevention pipeline: Up to $5,000,000 for clinical trials based on stage and scope of research
|
Durada
Applications are reviewed throughout the year. Check back regularly for additional joint funding opportunities with our partners in non-profits, government, and industry.
|
AVÍS IMPORTANT
Deadlines for 2024 RFPs:
LETTERS OF INTENT:
February 5, 2024
May 13, 2024
September 30, 2024
INVITED FULL PROPOSALS:
April 8, 2024
July 22, 2024
December 9, 2024
|